Research - Over the weekend, the scientific and investing communities had a first look at 1-year follow-up results for AMT-110, uniQure’s (QURE) gene therapy candidate for the treatment of Sanfilippo B.
Read nowResearch - UniQure’s (QURE) presentation of 1-year follow-up data from patients with Sanfilippo B (MPS IIIB) and treated with the gene therapy AMT-110 is only a week … Continue Reading
Read nowResearch - This weekend, bluebird bio (BLUE) and investigators presented much-awaited data for the first Sickle Cell Disease (SCD) patient treated with LentiGlobin (BB305) in the HBG-205 … Continue Reading
Read nowResearch - Updates on our Affimed (AFMD), Innate Pharma (IPH), and Oncothyreon (ONTY) coverage coming away from ASCO 2015.
PremiumResearch - Completing their IPO in September 2014 and raising $56 million, Affimed Therapeutics (AFMD) is a German clinical-stage biopharmaceutical company developing targeted cancer immunotherapies. Affimed’s product … Continue Reading
Read nowResearch - UniQure went through some interesting de-risking two weeks back with the release of initial data (the first publicly) from Baxter International’s (BAX) Hemophilia B gene therapy program, … Continue Reading
Read nowResearch - In early December we published Mr. Fink’s deep-dive on Innate Pharma (IPH.PA) (IPHYF), explaining why we wanted to own the stock in 2015.
Premium
